Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2011)	10/30/2007 10:46:02 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AMRN has been forming a base at the $0.35 level after it tanked on April 24. That was the day when it announced that the data in two different trials on HD patients,showed no statistically significant difference between its Miraxion & placebo with regard to the primary and secondary endpoints.(The primary endpoint was improvement on motor function & the secondary were improvement on cognition & functional capacity.) The stock was up 11.69% today with volume about 50% better than its ADV & it continued to trade up a little AHs. bigcharts.marketwatch.com Earlier this month AMRN announced that although neurology remains its core focus,it plans to expand into cardiovascular diseases & do some clinical trials with its AMR 101, which is 97% pure EPA & capitalize on existing assets which already have an established safety and efficacy profile in Japan By the end of this Yr. AMRN plans to start a series of trials with AMR 101 in dyslipidemia. It said that it believes proof of concept with AMR 101 in cardiovascular disease can be established relatively quickly and inexpensively as efficacy is measured by well defined biochemical endpoints & expects rapid progress of effective compounds into the final stages of development. More than 2M patients have received ultra-pure EPA in Japan for the treatment of high triglyceride levels & the safety profile of it is very good, especially in comparison to other triglyceride lowering agents such as fibrates, statins and niacin. If AMRN can get back to the $1 level it would be > 100% gain from present levels.<g> bigcharts.marketwatch.com AMRN doesn't have a large LTD & it trades around 0.8 x BV It seems the R/R isn't too bad at present.<g> But although it may have a chance to get back at $1, don't expect for it to get to the $10 or set your "target" too high.<g> bigcharts.marketwatch.com Bernard